Trial Profile
Phase II Study of Radiolabeled BC8 (Anti-CD45) Antibody Combined With Busulfan and Cyclophosphamide as Treatment for Acute Myelogenous Leukemia in First Remission Followed by HLA-Identical Related Peripheral Blood Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs I-131-Apamistamab (Primary) ; Busulfan; Cyclophosphamide
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 28 Aug 2017 Status changed from active, no longer recruiting to completed.
- 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual end date (Dec 2003) added as reported by ClinicalTrials.gov.